Phenytoin Injection Rx
Generic Name and Formulations:
Phenytoin 50mg/mL; contains alcohol, propylene glycol.
Various generic manufacturers
Indications for Phenytoin Injection:
Status epilepticus (tonic-clonic). Seizure prophylaxis and treatment in neurosurgery.
Status epilepticus: IV not to exceed 50mg/min. Loading dose: 10–15mg/kg followed by maintenance doses of 100mg orally or IV every 6–8 hrs. Do not dilute solution in IV fluids. Neurosurgical procedures: see full labeling.
Status epilepticus: IV not to exceed 1–3mg/kg/min. Loading dose: 15–20mg/kg. Neurosurgical procedures: see full labeling.
History of prior acute hepatotoxicity due to phenytoin. Heart block and sinus bradycardia. Adams-Stokes syndrome. Concomitant delavirdine.
Increased cardiovascular risk associated with rapid infusion; monitor during and after therapy; rate reduction or discontinuation may be needed. Hypotension. Severe myocardial insufficiency. Monitor ECG, BP, respiration, phenytoin levels. Diabetes. Change dose gradually. Monitor for signs/symptoms of serious dermatological reactions; discontinue if rash develops. Maintain proper dental hygiene. Oral contraception. Porphyria. Renal and/or hepatic impairment. Hypoalbuminemia. Elderly. Debilitated. Pregnancy (see full labeling). Nursing mothers.
See Contraindications. Potentiated by acute alcohol ingestion, amiodarone, benzodiazepines (eg, chlordiazepoxide, diazepam), chloramphenicol, dicumarol, disulfiram, estrogens, fluoxetine, halothane, H2 blockers (eg, cimetidine), isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinamides (eg, ethosuximide), sulfonamides, tolbutamide, trazodone, others. Antagonized by chronic alcohol ingestion, carbamazepine, reserpine, others. Antagonizes tricyclic antidepressants, oral anticoagulants, oral contraceptives, estrogens, corticosteroids, doxycycline, digitoxin, furosemide, theophylline, rifampin, quinidine, vitamins D and K, others. Variable effects with phenobarbital, valproic acid, divalproex, others. Absorption decreased by calcium.
Nystagmus, drowsiness, dizziness, insomnia, dyskinesias, ataxia, GI disturbances, gingival hyperplasia, osteomalacia, blood dyscrasias, atrial and ventricular conduction depression, slurred speech, lymphadenopathy, hepatic disease, rash, hyperglycemia, SLE, hypertrichosis, immunoglobulin abnormalities; DRESS, multiorgan hypersensitivity (may be fatal), local toxicity (eg, purple glove syndrome).
Sign Up for Free e-newsletters
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- A Witness to Letting Go: Nursing Care at the End of Life
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Ciprofloxacin Plus Doxycycline Reduces Infection Rate in Multiple Myeloma Post-ASCT
- Prognostic Significance of Epidermal Growth Factor Receptor Expression in Glioma Patients
- Fathers Can Pass Inherited Ovarian Cancer Risk to Daughters
- Modified XELIRI Noninferior to FOLFIRI for OS in Metastatic Colorectal Cancer
- Nabilone Improves Cancer-Associated Anorexia in Lung Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|